Omnipod 5 cleared for Type 2 diabetes management
By HME News Staff
Updated 9:22 AM CDT, Wed August 28, 2024
ACTON, Mass. – Insulet has received clearance from the U.S. Food and Drug Administration for its Omnipod 5 Automated Insulin Delivery System for people with Type 2 diabetes, making it the only such device cleared by the FDA for both Type 1 and Type 2 diabetes management. “Today’s announcement represents a significant milestone in providing easy-to-use, patient-centric technology for the treatment of Type 2 diabetes,” said Jim Hollingshead, Insulet president and CEO. “Insulet is paving the way for these individuals to achieve better health outcomes while living with greater confidence and freedom through the game-changing benefits of tubeless Pod therapy. Omnipod 5 is setting a new standard in diabetes management, and we are thrilled with the opportunity to make a lasting impact on the insulin-requiring Type 2 diabetes community.” The Omnipod 5 System simplifies diabetes management, eliminating the need for multiple daily injections and automatically adjusting insulin delivery every five minutes using its advanced SmartAdjust technology.
Comments